IONS - Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's Shifts Focus On Newer Medicines | Benzinga
Biogen Inc (NASDAQ:BIIB) is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the limelight after receiving controversial FDA approval.
Biogen said on Wednesday it would discontinue developing and commercializing Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use and terminate the ENVISION clinical study.
Related: Slow Market Penetration For Biogen’s Another Alzheimer’s Drug: UBS Highlights Risks, Forecasts.
Aduhelm received accelerated FDA approval in June 2021. The Phase 4 post-marketing confirmatory ENVISION study was a requirement of ...